A Phase 2 interventional study of 20% human serum albumin in Acute Ischemic Stroke From Large Vessel Occlusion, sponsored by Tianjin Huanhu Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Tianjin Huanhu Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Ischemic Stroke · Tianjin Huanhu Hospital.
Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, this one is the only one that started in 2026, is one of 2 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 12th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →10 of the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital are open now, in 1 country. Recruiting first, the newest first:
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tianjin Huanhu Hospital · Sites in China
Ages 18–80
Tianjin Huanhu Hospital · Sites in China
Ages 18+
Tianjin Huanhu Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 306 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 70 across the 6 interventional studies, 3,000 across the 6 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tianjin Huanhu Hospital is the lead sponsor of 26 studies on the registry; 20 are open to participants now.
1 of the studies in Ischemic Stroke by Tianjin Huanhu Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07294391Tianjin Huanhu HospitalThe Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Stroke remains a predominant global public health challenge, ranking as the third leading cause of death and the fourth leading contributor to disability-adjusted life years (DALYs). According to the Global Burden of Disease Study 2021, there are approximately 93.8 million prevalent stroke cases and 11.9 million new cases worldwide. China bears one of the heaviest burdens, with over 2 million new cases annually. Acute ischemic stroke (AIS), caused by acute cerebrovascular occlusion, accounts for 80% of all strokes. Approximately 30% of AIS cases result from large vessel occlusion (LVO), which typically carries a poor prognosis due to the extensive area of infarction . Research indicates that early recanalization significantly improves clinical outcomes. Currently, intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard treatments for achieving recanalization . For LVO-related AIS, MT has become the preferred clinical approach due to its extended therapeutic window and superior recanalization rates . However, despite successful recanalization in over 70% of patients, nearly 50% fail to achieve functional independence at 90 days, and mortality remains above 15% . Therefore, enhancing long-term functional outcomes in post-MT patients is a critical unmet clinical need. Human albumin is the most abundant protein in plasma. Beyond maintaining colloid osmotic pressure, it also possesses multiple biological effects, including anti-inflammatory, anti-platelet aggregation, antioxidant, and endothelial protective properties. We conducted a Phase I clinical trial (AMASS-1) for patients post-mechanical thrombectomy, administering human albumin via the internal carotid artery. The results showed that intra-arterial infusion of 20% human albumin at a dose of 0.60 g/kg was safe, with no significant differences in serious adverse reactions such as mortality [Albumin group (6.7%) vs Control group (6.7%), P > 0.05] and symptomatic intracranial hemorrhage [Albumin group (6.7%) vs Control group (13.3%), P > 0.05] compared to the control group. In summary, albumin adjunctive therapy demonstrates good safety and potential neuroprotective effects in patients after mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we plan to conduct a Phase II clinical trial of mechanical thrombectomy combined with intra-arterial albumin infusion for acute ischemic stroke. This is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the efficacy and safety of intra-arterial infusion of 20% human serum albumin combined with mechanical thrombectomy versus mechanical thrombectomy alone in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who have achieved recanalization after mechanical thrombectomy. A total of 306 patients are planned to be enrolled and randomly assigned in a 1:1 ratio using a dynamic minimization method to two groups: the Albumin Group (0.6 g/kg 20% human serum albumin plus Mechanical Thrombectomy) and the Control Group (Mechanical Thrombectomy alone). The primary efficacy objective of this study is to evaluate whether immediate intra-arterial infusion of 20% human albumin (0.6 g/kg) via the internal carotid artery following successful recanalization (eTICI ≥2b) improves clinical outcomes in patients with acute anterior circulation large vessel occlusion stroke, compared with mechanical thrombectomy alone. The study also aims to evaluate the safety and feasibility of immediate intra-arterial infusion of 20% human albumin (0.6 g/kg) via the internal carotid artery in patients with acute anterior circulation large vessel occlusion stroke who have achieved successful recanalization (eTICI ≥2b) following standard mechanical thrombectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Albumin Group Subjects assigned to the albumin treatment group after achieving successful recanalization (eTICI ≥ 2b) confirmed by DSA post-thrombectomy will receive a 20% human albumin solution at a dose of 0.60 g/kg. The solution will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes. Vital signs and potential infusion-related reactions must be closely monitored throughout the procedure. Mechanical thrombectomy must be performed using clinically approved devices. The specific technical approach is to be determined by the neurointerventional physician based on the patient's individual clinical condition.
Drug: 20% human serum albumin
Subjects in the control group who have achieved successful recanalization (eTICI ≥ 2b) as confirmed by DSA following mechanical thrombectomy will not receive the investigational infusion and will undergo standard medical management only. The mechanical thrombectomy procedure must be performed using clinically approved devices. The specific technical approach is to be determined at the discretion of the neurointerventional physician based on the patient's clinical condition.
20% human albumin solution at a dose of 0.60g/kg will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes.
Distribution of mRS scores at 90 (±14) days post-randomization
Distribution of mRS scores
Time frame: at 90 (±14) days post-randomization
Proportion of subjects with a favorable outcome at 90 (±14) days post-randomization (defined as mRS 0-2);
Proportion of subjects with a favorable outcome, defined as mRS 0-2
Time frame: at 90 (±14) days post-randomization
Proportion of subjects with functional independence at 90 (±14) days post-randomization (defined as mRS 0-1)
Proportion of subjects with functional independence, defined as mRS 0-1
Time frame: at 90 (±14) days post-randomization
Infarct volume at 24 (±6) hours post-randomization (measured via MRI-DWI)
Infarct volume, measured via MRI-DWI
Time frame: at 24 (±6) hours post-randomization
Infarct volume growth from baseline to 24 (±6) hours post-randomization
Infarct volume growth
Time frame: from baseline to 24 (±6) hours post-randomization
Recanalization rate at 24 (±6) hours post-randomization
Recanalization rate
Time frame: at 24 (±6) hours post-randomization
NIHSS score at 24 (±6) hours post-randomization
NIHSS score
Time frame: at 24 (±6) hours post-randomization
NIHSS score at 7 (±1) days or at discharge, whichever occurs first
NIHSS score
Time frame: at 7 (±1) days or at discharge, whichever occurs first
EQ-5D-5L score at 90 (±14) days post-randomization
EQ-5D-5L score
Time frame: at 90 (±14) days post-randomization
Proportion of subjects with a Barthel Index (BI) ≥95 at 90 (±14) days post-randomization
Proportion of subjects with a Barthel Index (BI)
Time frame: at 90 (±14) days post-randomization
Distribution of mRS scores at 180 (±30) days and 1 year (±30 days) post-randomization
Distribution of mRS scores
Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization
Proportion of subjects with a favorable outcome (mRS 0-2) at 180 (±30) days and 1 year (±30 days) post-randomization
Proportion of subjects with a favorable outcome (mRS 0-2)
Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization
EQ-5D-5L score at 180 (±30) days and 1 year (±30 days) post-randomization
EQ-5D-5L score
Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization
Proportion of subjects with a Barthel Index (BI) ≥95 at 180 (±30) days and 1 year (±30 days) post-randomization
Proportion of subjects with a Barthel Index (BI) ≥95
Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization
All-cause mortality within 90 (±14) days post-randomization
All-cause mortality
Time frame: within 90 (±14) days post-randomization
Symptomatic intracranial hemorrhage (sICH) at 24 (±6) hours post-randomization (according to ECASS III criteria)
Symptomatic intracranial hemorrhage (sICH) ,according to ECASS III criteria
Time frame: at 24 (±6) hours post-randomization
Serious adverse events (SAEs) within 90 (±14) days post-randomization
SAEs
Time frame: within 90 (±14) days post-randomization
Adverse events (AEs) within 90 (±14) days post-randomization
AEs
Time frame: within 90 (±14) days post-randomization
Early neurological deterioration (END), defined as an increase in NIHSS score of ≥4 points from baseline at 24 hours post-randomization
END, defined as an increase in NIHSS score of ≥4 points from baseline at 24 hours post-randomization
Time frame: from baseline at 24 hours post-randomization
Proportion of subjects with severe disability at 90 (±14) days post-randomization (defined as mRS 4-6)
Proportion of subjects with severe disability , defined as mRS 4-6
Time frame: at 90 (±14) days post-randomization
Albumin-related adverse events within 90 (±14) days post-randomization
Albumin-related adverse events
Time frame: within 90 (±14) days post-randomization
SAEs and AEs within 180 (±30) days post-randomization
SAEs and AEs
Time frame: within 180 (±30) days post-randomization
SAEs and AEs within 1 year (±30 days) post-randomization
SAEs and AEs
Time frame: within 1 year (±30 days) post-randomization
Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood at 24 (±6) hours post-randomization
Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood
Time frame: at 24 (±6) hours post-randomization
Serum albumin and B-type natriuretic peptide (BNP) levels at 24 (±6) hours post-randomization
Serum albumin and B-type natriuretic peptide (BNP) levels
Time frame: at 24 (±6) hours post-randomization
Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood at 7 (±1) days post-randomization or at discharge (whichever occurs first)
Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood
Time frame: at 7 (±1) days post-randomization or at discharge (whichever occurs first)
Serum albumin and BNP levels at 7 (±1) days post-randomization or at dis charge (whichever occurs first)
Serum albumin and BNP levels
Time frame: at 7 (±1) days post-randomization or at dis charge (whichever occurs first)
Net water uptake (NWU) at 24 (±6) hours post-randomization
Net water uptake (NWU)
Time frame: at 24 (±6) hours post-randomization
Progression of net water uptake from baseline to 24 (±6) hours post-randomization
Progression of net water uptake
Time frame: from baseline to 24 (±6) hours post-randomization
Cerebrospinal fluid (CSF) volume at 24 (±6) hours post-randomization
Cerebrospinal fluid (CSF) volume
Time frame: at 24 (±6) hours post-randomization
Change in cerebrospinal fluid volume from baseline to 24 (±6) hours post-randomization
Change in cerebrospinal fluid volume
Time frame: from baseline to 24 (±6) hours post-randomization
Analysis of the Index for Connectivity via Perivascular Spaces (ALPS index) at 24 (±6) hours post-randomization
Analysis of the Index for Connectivity via Perivascular Spaces (ALPS index)
Time frame: at 24 (±6) hours post-randomization
No study locations are listed for this record.
Start is estimated for Jan 2026; primary completion for Jun 2028, 29 months later.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 29 months is close to that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins human
Tianjin Huanhu Hospital